Southern Research Institute licensed rights to an oncology candidate to Virium Pharmaceuticals. In exchange, Southern Research will receive cash and stock in Virium and will hold seats on the company’s scientific advisory board and the board of directors.
SR9025 reportedly has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has completed two Phase I trials.
“This is the first anticancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline,” says John A. Secrist, III, Ph.D., president and CEO of Southern Research.